Filtered By:
Specialty: Hematology
Source: Expert Review of Hematology

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 38 results found since Jan 2013.

Hematological disorders: a commonly unrecognized cause of acute stroke.
Authors: Arboix A, Jiménez C, Massons J, Parra O, Besses C Abstract INTRODUCTION: Hematological disorders account for about 1.3% of all causes of acute stroke. This systematized review presents updated information on the implications of this category of heterogeneous diseases as a cause of stroke. AREAS COVERED: The most relevant aspects of the relationship between stroke and hematological disorders are reported. A high index of suspicion is needed in young stroke patients, patients with recurrent stroke of undetermined cause, and in patients with prior history of venous thrombosis to identify a potential hema...
Source: Expert Review of Hematology - July 3, 2016 Category: Hematology Tags: Expert Rev Hematol Source Type: research

Association between polycythemia and risk of ischemic stroke in males based on the National Health Insurance Service-Health Screening Cohort
CONCLUSIONS: The risk of ischemic stroke was higher in participants with polycythemia than in those with normocythemia.PMID:37249134 | DOI:10.1080/17474086.2023.2218610
Source: Expert Review of Hematology - May 30, 2023 Category: Hematology Authors: Hyo-Sun You Sang-Jun Shin Joungyoun Kim Hee-Taik Kang Source Type: research

Association between polycythemia and risk of ischemic stroke in males based on the national health insurance service-health screening cohort
CONCLUSIONS: The risk of ischemic stroke was higher in participants with polycythemia than in those with normocythemia.PMID:37249134 | DOI:10.1080/17474086.2023.2218610
Source: Expert Review of Hematology - May 30, 2023 Category: Hematology Authors: Hyo-Sun You Sang-Jun Shin Joungyoun Kim Hee-Taik Kang Source Type: research

The risk of stroke among acutely ill hospitalized medical patients: lessons from recent trials on extended-duration thromboprophylaxis.
Authors: Marszalek J, Mehrsefat S, Chi G Abstract Data from recent randomized controlled trials indicate that the incidence of stroke among acutely ill medical patients is unexpectedly high and approximates 1% at 90 days. Preliminary data suggest that betrixaban may reduce ischemic stroke in patients without atrial fibrillation. There is an unmet demand for stroke risk stratification schemes targeting hospitalized medical patients. The prognostic value of biomarkers such as natriuretic peptides and D-dimer in predicting short-term stroke remains uncertain. Future research should focus on identifying the high-risk s...
Source: Expert Review of Hematology - June 16, 2017 Category: Hematology Tags: Expert Rev Hematol Source Type: research

Real-world comparison of direct-acting oral anticoagulants and vitamin K antagonists in chronic kidney disease: a systematic review and meta-analysis
Conclusion: DOACs are associated with only a modest reduction in stroke or systemic embolism, major bleeding, and mortality when compared to VKA in CKD patients. Reduction in mortality and major bleeding with DOAC may only be seen in moderate-to-severe CKD patients.PMID:33949923 | DOI:10.1080/17474086.2021.1920012
Source: Expert Review of Hematology - May 5, 2021 Category: Hematology Authors: Rongfang Xu Fan Wu Jiarong Lan Peixin Duan Source Type: research

Direct factor Xa inhibitor edoxaban: from bench to clinical practice.
Authors: Brekelmans M, Middeldorp S, Coppens M Abstract Edoxaban is a direct factor Xa inhibitor and has become the fourth direct oral anticoagulant (DOAC) approved for stroke prevention in atrial fibrillation (AF) and for treatment and secondary prevention of venous thromboembolism (VTE). This review provides an overview of the key characteristics of edoxaban and clinical evaluation program leading to regulatory approval. Approval for AF and VTE treatment was based on large phase III randomized controlled trials that showed that edoxaban reduces the risk of bleeding compared with warfarin and provides similar prot...
Source: Expert Review of Hematology - February 14, 2016 Category: Hematology Tags: Expert Rev Hematol Source Type: research

Betrixaban - the next direct factor Xa inhibitor?
Authors: Thoenes M, Minguet J, Bramlage K, Bramlage P, Ferrero C Abstract INTRODUCTION: Venous thromboembolism is a major global health burden. Since the 1930s, prevention of stroke and pulmonary embolism in these patients has been achieved using conventional anticoagulants, such as heparin and warfarin. However, in recent years, four direct non-vitamin K antagonist oral anticoagulants (DOACs) have entered the market as alternative treatment options. Betrixaban is a fifth DOAC looking to gain marketing approval in the near future, and may have several potentially beneficial properties. Areas covered: Here, we outli...
Source: Expert Review of Hematology - November 6, 2016 Category: Hematology Tags: Expert Rev Hematol Source Type: research

Gender related issues in thrombosis and hemostasis.
Authors: Hvas AM, Favaloro EJ Abstract INTRODUCTION: Many aspects of hemostasis, both primary and secondary, as well as fibrinolysis display sex differences. From a clinical viewpoint, certain differential phenotypic presentations clearly arise within various disorders of thrombosis and hemostasis. Areas Covered: The present mini-review summarizes selected clinical entities where sex differences are reflected in both frequency and clinical presentation of hemostasis disorders. Sex differences are discussed within the settings of cardiovascular disease, including coronary artery disease and ischemic stroke, venous t...
Source: Expert Review of Hematology - August 24, 2017 Category: Hematology Tags: Expert Rev Hematol Source Type: research